ArticleFrontiers in pharmacology2026
A novel pyrrolidine-chalcone derivative exhibits synergistic anti-cervical cancer activity by dual-targeting MDM2-p53 axis and ferroptosis pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer remains a serious threat to women's health, driving the need for effective and low-toxicity therapeutics. This study designed novel pyrrolidine-chalcone derivatives targeting the MDM2-p53 interaction. Methods: A series of compounds were synthesized and evaluated for cytotoxicity against cervical cancer (HeLa, SiHa, C33A) and normal (H8) cells via CCK-8. The lead compound B1 was further analyzed for p53 pathway activation, apoptosis, and ferroptosis markers (ROS, GSH, MDA, Fe Results: Compound B1 showed potent, nanomolar cytotoxicity (IC Discussion: B1 is a promising dual-mechanism lead compound against cervical cancer, concurrently activating p53 and ferroptosis, warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.